Key result
Epicardial RVOT ablation prevents VF recurrence over 5 months in a single case report.
Why the study?
Does epicardial catheter ablation prevent recurrent ventricular fibrillation in patients with drug-refractory Brugada syndrome?
Case Report (n=1)
No
Does epicardial catheter ablation prevent recurrent ventricular fibrillation in patients with drug-refractory Brugada syndrome?
Epicardial substrate modification by catheter ablation in the RVOT may be an effective treatment for symptomatic, drug-refractory Brugada syndrome.
May support epicardial RVOT ablation in refractory Brugada VF; hypothesis-generating and requires prospective validation.
We report a case of catheter ablation of Brugada syndrome in a patient with refractory ventricular fibrillation despite quinidine therapy. We performed epicardial substrate mapping, which identified an area of abnormal fractionated, prolonged electrogram in the anterior right ventricular outflow tract. Warm saline infusion into the pericardial space induced further delay of the local electrogram, consistent with Brugada syndrome physiology. Coronary angiography confirmed that the area was distant from major coronary arteries. Ablation was performed in this area, which eliminated local abnormal electrograms and led to the disappearance of coved-type ST elevation in V1-V2. No ventricular fibrillation had recurred by five months of follow-up.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2021) conducted a case report in Brugada syndrome (n=1). Epicardial catheter ablation was evaluated on Recurrence of ventricular fibrillation. Epicardial catheter ablation of the right ventricular outflow tract eliminated abnormal local electrical activity and prevented recurrence of ventricular fibrillation over five months of follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: